araag2/HINT huggingface dataset:
Clinical trial NCT00400517 (phase 2, status: completed)
Conditions: prostate cancer
ICD codes: C61, D29.1, D40.0, Z15.03, Z80.42, Z85.46, Z12.5
Drugs: thalidomide
SMILES: CC(C)NCC(O)COC1=CC=CC2=C1C=CC=C2
Eligibility criteria:

        DISEASE CHARACTERISTICS:

          -  Histologically confirmed adenocarcinoma of the prostate meeting any of the following
             criteria for high-risk disease:

               -  Clinical stage II or III (T2b, T2c, or T3 with any grade or prostate-specific
                  antigen [PSA])

               -  Gleason score 7 (4+3 only) or ≥ 8 (any stage or PSA)

               -  Serum PSA ≥ 10 ng/dL (any grade or stage)

               -  Any stage, PSA, or Gleason score with ≥ 35% chance of biochemical failure at 5
                  years based on Kattan's nomogram

          -  No clinical evidence of CNS metastases

          -  No metastatic disease as demonstrated by radiological exam (CT scan, MRI, bone scan,
             x-ray) within 8 weeks of study entry

          -  Appropriate medical candidate for radical prostatectomy

        PATIENT CHARACTERISTICS:

          -  ECOG performance status 0-1

          -  Creatinine ≤ 2.0 mg/dL

          -  Granulocyte count ≥ 1,800/mm³

          -  Platelet count ≥ 100,000/mm³

          -  AST < 3 times upper limit of normal

          -  Bilirubin ≤ 1.5 mg/dL

          -  Fertile patients must use effective contraception during and for 4 weeks after
             completion of study treatment

          -  No active unresolved infection

          -  No pre-existing peripheral neuropathy > grade 1

          -  No known HIV positivity

          -  No other malignancy within the past 5 years except curatively treated basal cell or
             squamous cell carcinoma of the skin or controlled Ta transitional cell carcinoma of
             the bladder

          -  No known contraindication to sargramostim (GM-CSF) or thalidomide

        PRIOR CONCURRENT THERAPY:

          -  No prior radiotherapy to the prostate or pelvis

          -  No prior chemotherapy or hormonal therapy for prostate cancer

          -  No parenteral antibiotics within the past 7 days
Clinical trial NCT01217073 (phase 2, status: completed)
Conditions: type 2 diabetes mellitus
ICD codes: E11.65, E11.9, E11.21, E11.36, E11.41, E11.42, E11.44
Drugs: omarigliptin, placebo to omarigliptin, pioglitazone, metformin, placebo to metformin
SMILES: CS(=O)(=O)N1C=C2CN(CC2=N1)[C@H]1CO[C@@H]([C@@H](N)C1)C1=CC(F)=CC=C1F, CS(=O)(=O)N1C=C2CN(CC2=N1)[C@H]1CO[C@@H]([C@@H](N)C1)C1=CC(F)=CC=C1F, N[C@@H](CCCNC(N)=N)C(O)=O, CSCC[C@H](N)C(O)=O, CN(C)C(=N)NC(N)=N
Eligibility criteria:

        Inclusion Criteria:

        The prospective participant must meet, at least, all of the criteria below (among others
        determined by the study staff) to be eligible for study participation.

        The participant:

          -  Has type 2 diabetes mellitus and is between 18 and 70 years of age; for Japan, 20 to
             70 years of age;

          -  Has a body mass index (BMI) > 20 kg/m^2 and < 43 kg/m^2; for Japan: BMI >18 kg/m^2 and
             <43 kg/m^2;

          -  Is currently not on an antihyperglycemic agent (AHA) medication (off for ≥ 14 weeks)
             or is on oral AHA therapy but has inadequate glycemic control;

          -  Is a male, or a female who is highly unlikely to conceive.

        Exclusion Criteria:

        If the prospective participant meets any of the criteria below (among others determined by
        the study staff) they will NOT be eligible for study participation.

        The participant:

          -  Has a history of type 1 diabetes mellitus or a history of ketoacidosis;

          -  Is on a weight loss program or has started a weight loss medication within the prior 8
             weeks;

          -  Has required insulin therapy within 14 weeks prior to signing informed consent;

          -  Has a medical history of active liver disease (other than nonalcoholic hepatic
             steatosis), including chronic active hepatitis B or C, cirrhosis, or symptomatic
             gallbladder disease;

          -  Has congestive heart failure or has new or worsening signs or symptoms of coronary
             heart disease;

          -  Had any of the following disorders within the past 3 months: acute coronary syndrome,
             coronary artery intervention, stroke or transient ischemic neurological disorder;

          -  Has a history of malignancy or clinically important hematological disorder
Clinical trial NCT00334295 (phase 2, status: completed)
Conditions: endometrial carcinoma
ICD codes: C22.0, C22.1, C4A.9, C7B.1, D09.9, C4A.0, C4A.31
Drugs: fulvestrant
SMILES: [H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@]1([H])C3=CC=C(O)C=C3C[C@@H](CCCCCCCCCS(=O)CCCC(F)(F)C(F)(F)F)[C@@]21[H]
Eligibility criteria:

        Inclusion Criteria:

          -  Histologically confirmed, recurrent or metastatic endometrial carcinoma

          -  Postmenopausal

          -  Hormonreceptor positive

        Exclusion Criteria:

          -  Pre-treatment with Fulvestrant

          -  Previous endocrine therapy of the endometrial carcinoma

          -  Previous malignancy less than 3 years ago other than in situ carcinoma of the cervix,
             basal cell carcinoma or squamous carcinoma of the skin
Clinical trial NCT00233155 (phase 2, status: completed)
Conditions: herpes zoster, neuralgia, pain, hiv infections, peripheral nervous system diseases
ICD codes: B02.39, G50.0, M54.81, B02.22, M79.2, N50.82, R07.2, R07.82, R10.13, R10.33, R14.1, R52, Z21, G64, M35.06, P14.9, P14.8, C47.9, D36.10, R94.138
Drugs: capsaicin dermal patch
SMILES: COC1=C(O)C=CC(CNC(=O)CCCC\C=C\C(C)C)=C1
Eligibility criteria:

        Summary eligibility criteria:

          -  Subjects must be in good health and have successfully completed a past trial of
             NGX-4010 with no past occurrence of adverse events that would contraindicate further
             treatment.

          -  The time between the last study patch on the previous study and the first study patch
             on this study must be at least 12 weeks.

          -  Topical pain medications are exclusionary and require washout prior to study patch
             application for this study.

          -  Chronic, nontopical pain medications are allowed but must be stable (not as needed)
             for a defined period prior to first study patch application.

          -  Other specific inclusion and exclusion criteria must be met prior to enrollment on the
             study.
Clinical trial NCT00557011 (phase 2, status: completed)
Conditions: attention deficit disorder with hyperactivity
ICD codes: F90.2, F90.8, F90.9, F90.0, F90.1
Drugs: nrp104, adderall xr, placebo
SMILES: C[C@@H](CC1=CC=CC=C1)NC(=O)[C@@H](N)CCCCN, C[C@H](N)CC1=CC=CC=C1, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  males and non-pregnant females, aged 6-12 years DSM-IV-TR criteria for diagnosis of
             ADHD, combined or hyperactive-impulsive subtypes

          -  on stable regimen of stimulants for at least one month in the last six months and has
             shown adequate response to stimulants without unacceptable side effects

        Exclusion Criteria:

          -  co-morbid psychiatric diagnosis such as psychosis, bipolar illness, severe OCD, severe
             depressive or anxiety disorder

          -  history of seizure during the last 2 years, a tic disorder or Tourette's

          -  clinically significant ECG or laboratory abnormalities at screening or baseline

          -  taking clonidine or anticonvulsant drugs

          -  taking medications that affect blood pressure or heart rate
Clinical trial NCT00903396 (phase 2, status: terminated)
Conditions: anal cancer, carcinoma of the appendix, colorectal cancer, extrahepatic bile duct cancer, gallbladder cancer, gastric cancer, gastrointestinal carcinoid tumor, liver cancer, nausea and vomiting, pancreatic cancer, primary peritoneal cavity cancer, small intestine cancer
ICD codes: C21.1, C44.500, C44.590, D12.9, C21.8, C22.0, C22.1, C4A.9, C7B.1, D09.9, C4A.0, C4A.31, C05.2, C10.0, C16.0, C16.4, C17.0, C17.1, C17.2, C24.0, D13.5, C23, D37.6, C05.2, C10.0, C16.0, C16.4, C17.0, C17.1, C17.2, C7A.00, C7A.010, C7A.011, C7A.012, C7A.020, C7A.021, C7A.026, D13.4, Z85.05, C22.8, C78.7, C22.9, D37.6, R11.10, R11.12, R11.14, R11.11, K91.0, O21.2, O21.8, C25.3, C30.0, Z12.81, D14.0, C14.8, D37.09, Z86.003, Z85.818, C17.9, C78.4, D37.2, C17.8, D13.30, D13.39, Z12.13
Drugs: palonosetron hydrochloride
SMILES: [H][C@]12CCCC3=C1C(=CC=C3)C(=O)N(C2)[C@@H]1CN2CCC1CC2
Reason stopped: 
    slow accrual
  
Eligibility criteria:

        DISEASE CHARACTERISTICS:

          -  Diagnosis of primary gastrointestinal and/or retroperitoneal sarcoma

          -  Scheduled to undergo ≥ 3000 cGy or ≥ 3 weeks of external beam radiation to the abdomen

               -  Radiotherapy fields to extend between T11 and L3, and of a size ≥ 100 cm^2

          -  No brain metastases

        PATIENT CHARACTERISTICS:

          -  ECOG performance status 0-2

          -  Negative pregnancy test

          -  Not pregnant or nursing

          -  Fertile patients must use effective contraception

          -  Able to complete questionnaire(s) alone or with assistance

          -  Willing to return to NCCTG enrolling institution for follow-up

          -  Able to reliably take oral medication (for purposes of rescue medication)

          -  No hypersensitivity to palonosetron hydrochloride or other selective 5-HT3 receptor
             antagonists

          -  No comorbid systemic illness or other severe concurrent disease that, in the judgment
             of the investigator, would make the patient inappropriate for study entry or interfere
             significantly with the proper assessment of safety and toxicity of the prescribed
             regimens

          -  No nausea ≤ 48 hours prior to study enrollment

          -  No history of dystonic reactions to prochlorperazine or haloperidol or related agents

        PRIOR CONCURRENT THERAPY:

          -  See Disease Characteristics

          -  More than 7 days since prior agents known to have significant effects on emesis,
             including the following:

               -  Ondansetron

               -  Sedating antihistamines

               -  Antipsychotics

               -  Cannabinoids

               -  Corticosteroids

               -  Metoclopramide

               -  Narcotic analgesics

               -  Benzodiazepines

          -  More than 7 days since prior chemotherapy other than fluorouracil or capecitabine used
             as a radiosensitizer

          -  More than 7 days since of prior cetuximab

          -  More than 7 days since prior and no concurrent oral steroids

          -  No prior palonosetron hydrochloride
Clinical trial NCT01220947 (phase 2, status: completed)
Conditions: hepatitis c, chronic
ICD codes: B18.2, B18.0, B18.1, B18.8, B18.9, K71.3, K71.4
Drugs: copegus, danoprevir, danoprevir, danoprevir, pegasys, ritonavir
SMILES: NC(=O)C1=NN(C=N1)[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O, CC(C)(C)OC(=O)N[C@H]1CCCCC\C=C/[C@@H]2C[C@]2(NC(=O)[C@@H]2C[C@H](CN2C1=O)OC(=O)N1CC2=CC=CC(F)=C2C1)C(=O)NS(=O)(=O)C1CC1, CC(C)(C)OC(=O)N[C@H]1CCCCC\C=C/[C@@H]2C[C@]2(NC(=O)[C@@H]2C[C@H](CN2C1=O)OC(=O)N1CC2=CC=CC(F)=C2C1)C(=O)NS(=O)(=O)C1CC1, CC(C)(C)OC(=O)N[C@H]1CCCCC\C=C/[C@@H]2C[C@]2(NC(=O)[C@@H]2C[C@H](CN2C1=O)OC(=O)N1CC2=CC=CC(F)=C2C1)C(=O)NS(=O)(=O)C1CC1, CC(C)[C@H](N1CCCNC1=O)C(=O)N[C@H](C[C@H](O)[C@H](CC1=CC=CC=C1)NC(=O)COC1=C(C)C=CC=C1C)CC1=CC=CC=C1
Eligibility criteria:

        Inclusion Criteria:

          -  Adults patients, >/=18 years of age

          -  Chronic Hepatitis C, Genotype 1 and 4

          -  HCV RNA >/=50,000 IU/mL

          -  treatment-naive

        Exclusion Criteria:

          -  Patients with cirrhosis or incomplete/transition to cirrhosis

          -  Patients with other forms of liver disease, HIV infection, hepatocellular carcinoma or
             severe cardiac disease
Clinical trial NCT01158144 (phase 2, status: unknown status)
Conditions: non-small cell lung cancer
ICD codes: C78.00, C78.01, C78.02, D14.30, D14.31, D14.32, C34.2
Drugs: endostar, paclitaxel/carboplatin
SMILES: [H][N]([H])([H])[Pt]1(OC(=O)C2(CCC2)C(=O)O1)[N]([H])([H])[H]
Eligibility criteria:

        Inclusion Criteria:

          -  Histologically proven non-small cell lung cancer (squamous cell carcinoma,
             adenocarcinoma, large cell carcinoma and etc)

          -  Presence of measurable disease by RECIST

          -  stage IIIA or IIIB, non-resectable

          -  ECOG performance status 0-1

          -  No prior chemotherapy, radiation therapy to chest, immunotherapy, or biologic therapy
             .Patients must sign an informed consent indicating that they are aware of the
             .investigational nature of the study in keeping with the policy of the hospital.

        Exclusion Criteria:

          -  Carcinoid tumor, small cell carcinoma of lung

          -  Patients with any distant metastasis

          -  History of another malignancy except cured basal cell carcinoma of skin and cured
             carcinoma in-situ of uterine cervix

          -  Any other morbidity or situation with contraindication for radiotherapy (e.g. active
             infection, myocardial infarction preceding 6 months, symptomatic heart disease
             including unstable angina, congestive heart failure or uncontrolled arrhythmias,
             immunosuppressive treatment)

          -  Pregnant or lactating women, women who has not taken test of pregnancy (within 7 days
             before the first administration) and pregnant women

          -  Women and men of childbearing potential who have no willing of employing adequate
             contraception Tumor EGFR wild
Clinical trial NCT01171651 (phase 2, status: completed)
Conditions: carcinoma, hepatocellular
ICD codes: C22.0, C4A.9, C7B.1, C4A.0, C4A.31, C4A.51, C4A.8
Drugs: jx-594 followed by sorafenib
SMILES: CNC(=O)C1=NC=CC(OC2=CC=C(NC(=O)NC3=CC(=C(Cl)C=C3)C(F)(F)F)C=C2)=C1
Eligibility criteria:

        Inclusion Criteria:

          -  Histological confirmation or clinical/laboratory diagnosis of primary hepatocellular
             carcinoma (HCC)

          -  Cancer is not surgically resectable for cure

          -  Child Pugh A or B

          -  Performance Score: KPS score of ≥ 70

          -  Platelet count ≥ 50,000 plts/mm3

          -  Total bilirubin ≤ 2.5 x ULN

          -  AST, ALT < 5.0 x ULN

          -  Acceptable coagulation status: INR ≤ 1.5 x ULN

          -  Acceptable kidney function: Serum creatinine < 2.0 mg/dL

          -  Sorafenib naive or refractory to sorafenib therapy Tumor Status: At least one
             intrahepatic tumor, and at least ≥50% of the total intrahepatic viable tumor mass,
             measurable by CT and injectable under imaging-guidance (note: injected and/or viable
             tumors must be previously untreated or ≥20% increase in size since preceding
             local-regional treatment).

        Exclusion Criteria:

          -  Known contraindications to sorafenib

          -  Pregnant or nursing an infant

          -  Significant immunodeficiency due to underlying illness (e.g. hematological
             malignancies, congenital immunodeficiencies and/or HIV infection/AIDS) and/or
             medication (e.g. high-dose systemic corticosteroids)

          -  History of exfoliative skin condition (e.g. severe eczema, ectopic dermatitis, or
             similar skin disorder) that at some stage has required systemic therapy

          -  Clinically significant and/or rapidly accumulating ascites, peri-cardial and/or
             pleural effusions

          -  Severe or unstable cardiac disease

          -  Current, known CNS malignancy

          -  Use of anti-platelet or anti-coagulation medication

          -  Use of the following anti-viral agents: ribavirin, adefovir, cidofovir (within 7 days
             prior to the first treatment), and PEG-IFN (within 14 days prior to the first
             treatment).

          -  Patients with household contacts who meet any of these criteria unless alternate
             living arrangements can be made during the patient's active dosing period and for 7
             days following the last dose of study medication:

          -  Pregnant or nursing an infant

          -  Children < 12 months old

          -  History of exfoliative skin condition that at some stage has required systemic therapy

          -  Significant immunodeficiency due to underlying illness (e.g. HIV/AIDS) and/or
             medication
Clinical trial NCT00380783 (phase 2, status: terminated)
Conditions: cystitis, interstitial
ICD codes: N30.10, N30.11
Drugs: agn 203818
SMILES: C[C@H](C1=CNC(=S)N1)C1=C(C)C(C)=CC=C1
Eligibility criteria:

        Inclusion Criteria:

          -  Diagnosis of painful bladder syndrome/interstitial cystitis

          -  Moderate or severe bladder pain

        Exclusion Criteria:

          -  Any other uncontrolled disease

          -  Pregnant or nursing females
Clinical trial NCT01779453 (phase 2, status: completed)
Conditions: hypercholesterolemia
ICD codes: E78.01, E78.00, Z83.42
Drugs: etc-1002, placebo, atorvastatin
SMILES: CC(C)(CCCCCC(O)CCCCCC(C)(C)C(O)=O)C(O)=O, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, CC(C)C1=C(C(=O)NC2=CC=CC=C2)C(=C(N1CC[C@@H](O)C[C@@H](O)CC(O)=O)C1=CC=C(F)C=C1)C1=CC=CC=C1
Eligibility criteria:

        Inclusion Criteria:

          -  For subjects on current daily statin therapy - LDL-C 100-220 mg/dL and triglycerides
             <350 mg/dL (prior to switching to sponsor -provided atorvastatin 10 mg/day and
             stopping all other lipid-regulating drugs and supplements) at the S1 Visit,

          -  For subjects not on current daily statin therapy - LDL-C ≥ 110 mg/dL and ≤ 220 mg/dL

        Exclusion Criteria:

          -  Acute significant cardiovascular disease

          -  Uncontrolled hypertension
Clinical trial NCT00003062 (phase 2, status: completed)
Conditions: lung cancer
ICD codes: C78.00, C78.01, C78.02, D14.30, D14.31, D14.32, C34.2
Drugs: temozolomide
SMILES: CSCC[C@H](N)C(O)=O
Eligibility criteria:

        DISEASE CHARACTERISTICS: Histologically confirmed progressive or recurrent stage IV
        non-small cell lung cancer (NSCLC) Patient with brain metastases on CT or MRI scan are
        included Symptomatic cases must have had brain radiotherapy at least one month prior to
        registration Patients without brain metastases: At least one target lesion Bidimensionally
        measurable Not previously irradiated

        PATIENT CHARACTERISTICS: Age: Under 70 Performance status: WHO 0-2 Life expectancy: Not
        specified Hematopoietic: Absolute neutrophil count greater than 2,000/mm3 WBC greater than
        3,500/mm3 Platelet count greater than 100,000/mm3 Hepatic: Bilirubin no greater than 1.46
        mg/dL Transaminases less than 2 times upper limit of normal Renal: Creatinine no greater
        than 1.70 mg/dL Creatinine clearance greater than 60 mL/min Other: No prior or concurrent
        malignancies at other sites with the exception of adequately treated in situ carcinoma of
        the cervix or basal and squamous carcinoma of the skin Not pregnant or nursing Negative
        pregnancy test 24 hours prior to commencing temozolomide

        PRIOR CONCURRENT THERAPY: No other investigational drugs allowed during this study Biologic
        therapy: Prior biologic therapy allowed No concurrent biologic therapy allowed No
        concurrent growth factor to induce neutrophil increase No concurrent erythropoietin
        Chemotherapy: No prior chemotherapy for metastatic disease At least 3 months since any
        neoadjuvant and adjuvant treatment, and induction chemotherapy preceding radical
        radiotherapy Endocrine therapy: See Protocol Outline Concurrent steroids should be
        maintained on the lowest dose possible Radiotherapy: Prior radiotherapy allowed Concurrent
        local radiotherapy to nonbrain lesions allowed Concurrent palliative radiation therapy of
        bone lesions permitted No concurrent radiation to target lesions No concurrent brain
        radiotherapy Surgery: Prior surgery allowed
Clinical trial NCT00166543 (phase 2, status: completed)
Conditions: breast cancer
ICD codes: C79.81, D24.1, D24.2, D24.9, D49.3, C44.501, D48.60
Drugs: tas-108
SMILES: OC(=O)CC(O)(CC(O)=O)C(O)=O.CCN(CC)CC1=CC=C(OCC[C@H]2CC[C@H]3[C@@H]4[C@H](C)CC5=C(C=CC(O)=C5)[C@H]4CC[C@]23C)C(OC)=C1
Eligibility criteria:

        Inclusion Criteria:

          -  Postmenopausal females

          -  Histologically or cytologically confirmed diagnosis of breast carcinoma

          -  Locally advanced or locally recurrent inoperable or metastatic breast carcinoma with
             documented disease progression

          -  Has laboratory documentation of positive estrogen receptor (ER) and/or progesterone
             receptor (PgR) status, and has responded to the standard first or second line hormonal
             anti-tumor therapy given

          -  Has received and whose disease progressed after one or two prior systemic hormonal
             anti-tumor therapies

          -  Performance status of greater than or equal to 2 on the Zubrod scale

          -  Predicted life expectancy of greater than or equal to 12 weeks

          -  Must give written informed consent

          -  Measurable disease according to the Response Evaluation Criteria in Solid Tumors
             (RECIST) criteria

          -  Absolute granulocyte count of greater than 1,500/meqL, platelet count greater than
             75,000/meqL, and a hemoglobin of greater than 10 g/dL

          -  Adequate liver and renal function as defined by a bilirubin of less than 1.5 times the
             upper limit of normal and a creatinine of less than 1.5 times the upper limit of
             normal

          -  Transaminases must be less than 2.5 times the upper limit of normal except for
             patients with liver metastases who may have transaminases less than 5 times the upper
             limit of normal.

          -  The patient has recovered from all previous anti-cancer treatment related to
             toxicities to at least Grade 1.

          -  All previous investigational drugs must be stopped at least four weeks before
             commencement of treatment with TAS-108.
Clinical trial NCT00135512 (phase 2, status: completed)
Conditions: depressive disorder
ICD codes: F25.1, F33.0, F33.1, F33.9, F32.0, F32.1, F32.9
Drugs: bupropion hydrochloride
SMILES: CC(NC(C)(C)C)C(=O)C1=CC(Cl)=CC=C1
Eligibility criteria:

        Inclusion criteria:

          -  Met DSM-IV-TR criteria for major depressive disorder for their current episode for at
             least 8 weeks prior to screening visit.

          -  Must give a written informed consent. But if the patient is under 20, both the patient
             himself/herself and his/her proxy consenter must give written informed consent.

          -  Must have rating scores as outlined.

        Exclusion criteria:

          -  Current or past history of seizure disorder or brain injury.

          -  Current or past history of anorexia or bulimia nervosa.

          -  History of manic episode.

          -  Past or current DSM- IV-TR diagnosis of schizophrenia or other psychotic disorder.

          -  Diagnosis of substance abuse (alcohol or drug) by the DSM-IV-TR criteria.

          -  Pregnant, possibly pregnant or lactating.

          -  Must not be suicidal.

          -  Blood pressure of SBP>160mmHg, DBP>100mmHg.

          -  History or complication of cancer or malignant tumour.